A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

Abstract

Objective. To compare the efficacy of two sequential 17β-estradiol (17β-E₂)/trimegestone (TMG) combinations with the sequential estradiol valerate (E₂V)/norethisterone (NET) regimen in relieving climacteric symptoms.

Study design. This was a double-blind, randomized, multicenter study conducted among 1218 Caucasian (99%) postmenopausal women with an intact uterus in seven European countries and Israel, over 13 cycles (each of 28 days). Study duration was extended further for 13 cycles, with 531 women receiving treatment for up to 26 cycles. Treatments consisted of 1 mg 17β-E₂ on days 1–14 and 1 mg 17β-E₂/0.125 mg TMG or 0.25 mg TMG on days 15–28, and 1 mg E₂V on days 1–16 and 1 mg E₂V/1 mg NET on days 17–28.

Results. Rapid and significant reductions in the mean daily number and severity of hot flushes and in the mean daily number of nocturnal sweats were established in most women with 1 mg 17β-E₂/0.25 mg TMG and E₂V/NET. These treatments also induced a significant improvement in the quality-of-life assessments.

Conclusion. The 1 mg 17β-E₂/0.25 mg TMG regimen provides rapid and effective relief of menopausal symptoms, with a reduction in the number of hot flushes ‘at least as good as’ that of the E₂V/NET comparator.

• 17β-estradiol
• trimegestone
• norethisterone
• sequential regimen
• vasomotor symptoms
• hormone replacement therapy
• hot flush
• quality of life